View in EDS

Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study

Saved in:
Bibliographic Details
Title: Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
Authors: Vuylsteke, P.1 peter.vuylsteke@cmsenamur.be, Huizing, M.2, Petrakova, K.3, Roylance, R.4, Laing, R.5, Chan, S.6, Abell, F.7, Gendreau, S.8, Rooney, I.9, Apt, D.10, Zhou, J.11, Singel, S.9, Fehrenbacher, L.12
Source: Annals of Oncology. Nov2016, Vol. 27 Issue 11, p2059-2066. 8p. 1 Diagram, 3 Charts, 1 Graph.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdw320